The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The role of NKTR-102 in women with platinum resistant/refractory ovarian cancer and failure on pegylated liposomal doxorubicin (PLD).
A. A. Garcia
Research Funding - Nektar
I. B. Vergote
Research Funding - Nektar
J. P. Micha
Research Funding - Nektar
C. H. Pippitt
Research Funding - Nektar
G. G. Rao
Research Funding - Nektar
D. L. Spitz
Research Funding - Nektar
N. Reed
Research Funding - Nektar
G. G. Dark
Research Funding - Nektar
E. N. Ibrahim
Research Funding - Nektar
V. A. Armenio
Research Funding - Nektar
L. R. Duska
Research Funding - Nektar
C. J. Poole
Research Funding - Nektar
C. Gennigens
Research Funding - Nektar
L. Y. Dirix
Research Funding - Nektar
J. West
Employment or Leadership Position - Nektar
C. Zhao
Employment or Leadership Position - Nektar
A. C. Leung
Employment or Leadership Position - Nektar
Stock Ownership - Nektar
L. K. Masuoka
Employment or Leadership Position - Nektar
G. J. S. Rustin
Research Funding - Nektar